Peutz-Jeghers polyps, dysplasia, and K-ras codon 12 mutations

M M Entius, A M Westerman, F M Giardiello, M-L F van Velthuisen, M M Polak, R J C Slebos, J H P Wilson, S R Hamilton, G J A Offerhaus

Department of
Pathology, Academic
Medical Centre,
University of
Amsterdam, The
Netherlands
M M Entius
M M Polak
R J C Slebos
G J A Offerhaus

Department of
Internal Medicine II,
University Hospital
Rotterdam, The
Netherlands
A M Westerman
J H P Wilson

Department of
Pathology, University
Hospital Rotterdam,
The Netherlands
M-L F van Velthuisen

Department of
Pathology and
Oncology Centre, The
Johns Hopkins
University School of
Medicine, Baltimore,
USA
S R Hamilton

Department of
Medicine, Division of
Gastroenterology, The
Johns Hopkins
University School of
Medicine, Baltimore,
USA
F M Giardiello

Correspondence to:
Professor Dr G J A
Offerhaus, Department of
Pathology, Academic
Medical Centre,
Meibergdreef 9, 1105 AZ
Amsterdam, The
Netherlands.

Accepted for publication
20 December 1996

Abstract

Background—Peutz-Jeghers syndrome (PJS) is a rare, autosomal dominant, polyposis syndrome, associated with an increased risk of gastrointestinal and extragastrointestinal malignancy. Occasionally dysplasia occurs in PJS polyps.

Aims—In colorectal carcinomas, mutations in codon 12 of the K-ras oncogene are common and are found at similar frequency in precursor adenomas. Therefore, K-ras codon 12 point mutations in PJS polyps were evaluated.

Materials and methods—Fifty two PJS polyps, including four with dysplasia, collected from 19 patients with PJS, were analysed for mutations in the K-ras codon 12 by a mutant enriched polymerase chain reaction procedure, followed by allele specific oligodeoxynucleotide hybridisation.

Results—A K-ras codon 12 mutation was identified in one colonic polyp with dysplasia. The mutation was found in the non-neoplastic epithelial cells and not in the dysplastic component of the polyp.

Conclusions—K-ras codon 12 point mutations are very rare in PJS polyps, by contrast with colorectal adenomas. The findings support previous evidence that there seems to be no intrinsic relation between K-ras codon 12 mutation and dysplasia.

(Gut 1997; 41: 320-322)

Keywords: Peutz-Jeghers syndrome; polyps; dysplasia; K-ras codon 12 mutations

Peutz-Jeghers syndrome (PJS) is a rare autosomal dominant disorder defined by hamartomatous polyposis of the gastrointestinal tract and the occurrence of melanin spots on the lips and buccal mucosa.^{1,2} Polyps primarily occur in the small bowel, but are also found in the stomach and colon, and they range in size from a few millimeters to several centimeters. PJS polyps are classified as hamartomas because they are composed of epithelium consisting of the cellular elements normally present at that particular site of the gut and an excessive proliferation of smooth muscle extending into the lamina propria in an arborisation-like fashion.³ Patients with PJS can present with intussusception, anaemia, gastrointestinal bleeding, and intestinal obstruction. The germline mutation(s) responsible for PJS are as yet unknown, although linkage to chromosome 19p is reported.⁴

The hamartomatous polyps are not generally regarded as premalignant lesions.⁵ However, patients with PJS have a high relative risk of both intestinal and extraintestinal malignancies.⁶⁻¹⁰ Although no apparent direct relation exists between polyp formation and the risk of carcinoma formation, dysplasia is occasionally found in PJS polyps. By analogy to the adenoma-carcinoma sequence in colorectal cancer,¹¹ carcinomas in the gastrointestinal tract may form due to progression of hamartoma to dysplasia to carcinoma. Molecular genetic alterations identifiable in hamartomatous PJS polyps might give an insight into the nature of the neoplastic risk. Tumorigenesis in the gastrointestinal tract results from an interaction between activation of dominantly acting oncogenes and inactivation of recessive tumour suppressor pathways.¹¹ In the large bowel, the *ras* oncogene family is known to be involved in the adenoma-carcinoma sequence.¹¹ The *ras* oncogenes encode for closely related 21 kDa proteins that function in cellular signal transduction, providing growth advantage. These proteins acquire transforming potential when altered at certain critical positions, in codons 12, 13, and 61.¹² Activation of the *ras* oncogenes (*H-ras*, *K-ras* and *N-ras*) is seen in about 50% of colorectal cancers and their precursor adenomas.¹² The most often encountered mutations are in codon 12 of K-ras and account for about 75% of *ras* mutations in tumours of the gastrointestinal tract. In this report we describe the analysis of 52 hamartomatous PJS polyps for K-ras mutations.

Methods

TISSUE SPECIMENS

Fifty two PJS polyps were collected from the pathology archives of the Academic Medical Centre of the University of Amsterdam, the University Hospital Rotterdam, and the Bowel Tumor Working Group Registry at The Johns Hopkins University School of Medicine. These were all hamartomatous polyps from the gastrointestinal tract (stomach n=4, duodenum n=14, small intestine n=18, large bowel

TABLE 1 Histological characterisation of 52 polyps obtained from 19 patients with Peutz-Jeghers syndrome

	Polyps without dysplasia	Polyps with dysplasia	Total
Stomach	4	0	4
Duodenum	12	2	14
Small bowel	18	0	18
Colorectum	14	2*	16
Total	48	4	52

*One polyp had a K-ras codon 12 mutation.

Figure 1: (A) Non-dysplastic and (B) dysplastic microscopic sections from the PJS polyp positive for a *K-ras* codon 12 mutation. This polyp shows heterogeneity for the *K-ras* mutation with the mutation solely found in the non-dysplastic section (haematoxylin and eosin).

n=16), obtained from 19 patients with PJS (table 1). The diagnosis of dysplasia was derived from the pathology reports of the original institutions and confirmed by review of the slides. Specimens of normal gastroenterocolonic mucosa were also analysed in all the patients.

TISSUE PREPARATION AND *K-ras* CODON 12 ANALYSIS

Archival specimens were cut into 5 µm sections, mounted on to glass slides, and non-dysplastic and dysplastic areas of polyp tissue were microdissected. The tissue was collected in microcentrifuge tubes containing 50–200 µl DNA isolation buffer (50 mM TRIS-HCl, pH 8.0, 0.2% Tween-20, and 100 mg/ml proteinase K) depending on the size of the tissue fragments and incubated at 56°C for 18–24 hours. Samples were heated to 95°C for 10 minutes to inactivate the proteinase K and to denature the DNA. After this treatment, the samples were analysed for *K-ras* codon 12 using a modified version of a previously described protocol.¹³ *K-ras* point mutations were evaluated by amplification of the sample DNAs, restriction

Figure 2: Autoradiograph of *K-ras* codon 12 point mutation analysis in PJS polyps. Left column of the panels: mutant unenriched PCR products. Right column: mutant enriched PCR products. Row 1, positive control for wild type *K-ras* codon 12 (left column), positive controls for wild type *K-ras* codon 12, Arg mutant *K-ras*, and Val mutant *K-ras* (right column), respectively. Rows 2 and 3, PCR products from dysplastic section of the polyp with *K-ras* mutation (in duplicate). Rows 4 and 5, PCR products of non-dysplastic section (in duplicate). Row 6, PCR product of PJS polyp negative for *K-ras* codon 12 mutation. Row 7, PCR products from the entire PJS polyp positive for the *K-ras* mutation. Row 8, positive (placenta DNA) PCR control. Row 9, buffer only (negative) PCR control.

enzyme digestion using *Mva*I (an isoschizomer of *Bst*NI; Boehringer Mannheim, Mannheim, Germany), reamplification of the digested and undigested polymerase chain reaction (PCR) products, and allele specific oligodeoxynucleotide hybridisation. For the first round of PCR sample DNA was amplified for 15 cycles (94°C 30 seconds; 62°C 30 seconds; 72°C 60 seconds) with primers A (5'-ACT GAA TAT AAA CTT GTG GTA GTT GGA CCT-3') and D (5'-TCA TGA AAA TGG TCA GAG AAA CC-3'). To enrich for the *K-ras* codon 12 mutants, the PCR products were then digested with *Mva*I to concentrate the mutant *K-ras* DNA fragments. Subsequently, a second round PCR was performed on both the digested and undigested first round PCR products. In the second round PCR, DNA was amplified for 35 cycles (94°C 30 seconds; 55°C 30 seconds; 72°C 60 seconds) using primers A and B (5'-TCA AAG AAT GGT CCT GGA CC-3'). After denaturation the undigested and digested PCR products were spotted on to seven different nylon membranes (Genescreen Plus, NEN Research Products, Boston, MA, USA) and hybridised to each of the *K-ras* codon 12 specific oligodeoxynucleotides, as described previously.¹⁴ Positive controls comprised plasmid clones harbouring each of the possible sequence variations in codon 12. Final stringency washes were carried out at 63°C, followed by autoradiography. All analyses for *K-ras* codon 12 mutations were performed in duplicate in two independently isolated DNA specimens.

Results

A *K-ras* codon 12 mutation—with the wild type codon GGT (glycine) mutated to GTT (valine)—was identified in the DNA of one colonic polyp (figs 1 and 2). After separating the dysplastic epithelium from the remaining polyp tissue by microdissection, the mutation was solely found in the non-dysplastic area (fig 1), whereas the dysplastic epithelium lacked the mutation. No additional *K-ras* mutations were identified in the remaining 51 hamartomatous gastrointestinal polyps, of which three contained dysplasia (table 1). Also, in the 52 samples of the normal adjacent mucosa, no *K-ras* codon 12 mutations were found.

Discussion

Hamartomatous PJS polyps have a neoplastic potential,¹⁵ but our study shows that activated *K-ras* plays no obvious part in the process. In a previous cytogenetic study a normal karyotype was found in PJS polyps.¹⁶ To our knowledge, these are the first findings of a difference in genetic make up between hamartomatous PJS polyps and adenomatous polyps of the colorectum.

Of particular note, the DNA from the dysplastic epithelium of the PJS polyp with the mutation showed wild type *K-ras* at codon 12 and the mutation was found in the non-dysplastic epithelium. Our finding raises questions about the role of *ras* mutations in colorectal carcinogenesis.

Aberrant crypt foci are microscopical lesions speculated to precede adenomatous polyp development. *Ras* mutations are often found in aberrant crypt foci in the mucosa of patients, but these lesions usually lack dysplasia.^{17–19} By contrast, another event—for example, inactivation of the APC gene—seems to be needed to provide the dysplastic phenotype.¹⁷ Apparently, *ras* activation provides a growth advantage but does not contribute to neoplastic transformation.

In summary, *K-ras* codon 12 mutations are very rare events in PJS polyps, by contrast with the high frequency of *ras* activation in adenomas and carcinomas of the large bowel. Furthermore, an intrinsic relation between *K-ras* codon 12 mutation and dysplasia was not noted. Further investigation is needed to elucidate the role and timing of *K-ras* oncogene

mutation in various forms of colorectal tumorigenesis.

- 1 Peutz JLA. Over een zeer merkwaardige, gecombineerde familiale polyposis van de slijmvliezen van den tractus intestinalis met die van de neuskeelholte en gepaard met eigenaardige pigmentaties van de huid en slijmvliezen. *Nederlandsch Maandschrift voor Geneeskunde* 1921; **10**: 134–6.
- 2 Jeghers H, McKusick VA, Katz KH. Generalized intestinal polyposis and melanin spots of the oral mucosa, lips and digits. *N Engl J Med* 1949; **241**: 993–1031.
- 3 Haggitt RC, Reid BJ. Hereditary gastrointestinal polyposis syndromes. *Am J Surg Pathol* 1986; **10**: 871–87.
- 4 Hemminki A, Tomlinson I, Markie D, Järvinen H, Sistonen P, Björkqvist A-M, et al. Localisation of a susceptibility locus for Peutz-Jeghers syndrome to 19p using comparative genomic hybridization and targeted linkage analysis. *Nat Genet* 1997; **15**: 87–90.
- 5 Spigelman AD, Murday V, Phillips RKS. Cancer and the Peutz-Jeghers syndrome. *Gut* 1989; **30**: 1588–90.
- 6 Giardiello F, Welsh SB, Hamilton SR, Offerhaus GJA, Gittelsohn AM, Booker SV, et al. Increased risk of cancer in the Peutz-Jeghers syndrome. *N Engl J Med* 1987; **316**: 1511–4.
- 7 Utsunomiya J, Gocho H, Miyahara T, Hamaguchi E, Kashimura A. Peutz-Jeghers syndrome: its natural course and management. *Johns Hopkins Medical Journal* 1975; **136**: 71–82.
- 8 Perzin KH, Bridge MF. Adenomatous and carcinomatous changes in hamartoma-tous polyps of the small intestine (Peutz-Jeghers syndrome): report of a case and review of the literature. *Cancer* 1982; **49**: 971–83.
- 9 Settaf A, Mansori F, Bargash S, Saidi A. Peutz-Jeghers syndrome with carcinoma degeneration of a duodenal hamartomatous polyp. *Ann Gastroenterol Hepatol* 1990; **26**: 285–8.
- 10 Hizawa K, Iida M, Matsumoto T, et al. Cancer in the Peutz-Jeghers syndrome. *Cancer* 1993; **72**: 2777–81.
- 11 Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. *N Engl J Med* 1988; **319**: 525–32.
- 12 Bos JL. *ras* Oncogenes in human cancer: a review. *Cancer Res* 1989; **49**: 4682–9.
- 13 Hruban RH, Van Mansfeld ADM, Offerhaus GJA, Van Weering DHJ, Allison DC, Goodman SN, et al. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. *Am J Pathol* 1993; **143**: 545–54.
- 14 Slebos RJC, Boerrigter L, Evers SG, Wisman P, Mooi WJ, Rodenhuis S. A rapid and simple procedure for detection of *ras* mutations in formalin-fixed paraffin-embedded tissue. *Diagn Mol Pathol* 1992; **1**: 136–42.
- 15 Hizawa K, Iida M, Matsumoto T, Kohrogi N, Yao T, Fujishima M. Neoplastic transformation arising in Peutz-Jeghers polyposis. *Dis Colon Rectum* 1993; **36**: 953–7.
- 16 Griffin CA, Lazar S, Hamilton SR, Giardiello FM, Long P, Krush A, et al. Cytogenetic analysis of intestinal polyps in polyposis syndromes: comparisons with sporadic colorectal adenomas. *Canadian Journal of Genetic Cytology* 1993; **67**: 14–20.
- 17 Jen J, Powell SM, Papadopoulos N, Smith KJ, Hamilton SR, Vogelstein B, Kinzler KW. Molecular determinants of dysplasia in colorectal lesions. *Cancer Res* 1994; **54**: 5523–6.
- 18 Smith AJ, Stern HS, Penner M, Hay K, Mitri A, Bapat BV, Gallinger S. Somatic APC and K-ras codon 12 mutations in aberrant crypt foci from human colons. *Cancer Res* 1994; **54**: 5527–30.
- 19 Chaubert P, Benhattar J, Saraga E, Costa J. K-ras mutations and p53 alterations in neoplastic and nonneoplastic lesions associated with longstanding ulcerative colitis. *Am J Pathol* 1994; **144**: 767–75.